

AXIRON® NET SALES, QUARTER TO 31 DECEMBER 2016

Acrux (ASX: ACR) today confirmed that Eli Lilly and Company reported global Axiron net sales of US\$39.9 million in its financial results for the quarter ending 31 December 2016, up from US\$39.0 million for the previous quarter to 30 September 2016.

Axiron net sales for the 2016 and 2015 calendar years are shown in the following table:

Q1 2016	Q2 2016	Q3 2016	Q4 2016	Total 2016
US\$37.0m	US\$29.3m	US\$39.0m	US\$39.9m	US\$145.2m
Q1 2015	Q2 2015	Q3 2015	Q4 2015	Total 2015
US\$39.1m	US\$32.4m	US\$41.4m	US\$41.6m	US\$154.5m

To date, there has been no launch of a generic of Axiron.

For further information, contact

Michael Kotsanis, CEO and Managing Director: 03 8379 0100

About Acrux

Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising specialty and generic topical pharmaceuticals. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of pharmaceutical products in the US and Europe using the Patchless Patch™, a fast-drying and invisible topical application technology. Marketed products include Axiron®, Evamist® and Lenzetto®. More recently, in addition to specialty products, Acrux has identified and initiated development of a range of generic products. Acrux is leveraging its on-site laboratories, GMP manufacturing suite, clinical and commercial experience to bring more products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.

For further information on Acrux, visit www.acrux.com.au

